Safety and Effect of SANGUINATE™ Infusion in Patients at Risk of Delayed Cerebral Ischemia (DCI) Following Subarachnoid Hemorrhage (SAH)
NCT02323685
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
12
Enrollment
INDUSTRY
Sponsor class
Conditions
Cerebral Ischemia
Interventions
BIOLOGICAL:
SANGUINATE™
Sponsor
Prolong Pharmaceuticals